HK1119771A1 - Devices and methods for diagnosing or predicting early stage cardiac dysfunctions - Google Patents

Devices and methods for diagnosing or predicting early stage cardiac dysfunctions

Info

Publication number
HK1119771A1
HK1119771A1 HK08111542.2A HK08111542A HK1119771A1 HK 1119771 A1 HK1119771 A1 HK 1119771A1 HK 08111542 A HK08111542 A HK 08111542A HK 1119771 A1 HK1119771 A1 HK 1119771A1
Authority
HK
Hong Kong
Prior art keywords
devices
methods
diagnosing
early stage
cardiac dysfunctions
Prior art date
Application number
HK08111542.2A
Other languages
English (en)
Inventor
Ildiko Amann-Zalan
Bernhard Trauth
Otero Jose Miguel Rivera
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1119771A1 publication Critical patent/HK1119771A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • External Artificial Organs (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Electrotherapy Devices (AREA)
HK08111542.2A 2005-05-09 2008-10-17 Devices and methods for diagnosing or predicting early stage cardiac dysfunctions HK1119771A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010043A EP1722232A1 (en) 2005-05-09 2005-05-09 Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
PCT/EP2006/062031 WO2006120152A1 (en) 2005-05-09 2006-05-03 Devices and methods for diagnosing or predicting early stage cardiac dysfunctions

Publications (1)

Publication Number Publication Date
HK1119771A1 true HK1119771A1 (en) 2009-03-13

Family

ID=34936290

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111542.2A HK1119771A1 (en) 2005-05-09 2008-10-17 Devices and methods for diagnosing or predicting early stage cardiac dysfunctions

Country Status (10)

Country Link
US (1) US20110104813A1 (xx)
EP (2) EP1722232A1 (xx)
JP (1) JP4927825B2 (xx)
CN (2) CN103091497A (xx)
AT (1) ATE482398T1 (xx)
CA (1) CA2605247A1 (xx)
DE (1) DE602006017058D1 (xx)
ES (1) ES2352351T3 (xx)
HK (1) HK1119771A1 (xx)
WO (1) WO2006120152A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
JP2010517023A (ja) * 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
US20120115929A1 (en) 2009-04-29 2012-05-10 Esther Elisa Johanna Maria Creemers Means And Methods For Counteracting, Preventing And/Or Determining Heart Failure, Or A Risk Of Heart Failure
EP2646822B1 (en) * 2010-11-29 2017-11-01 Alere San Diego, Inc. Methods for diagnosis and risk prediction in heart failure
WO2014023820A1 (en) 2012-08-09 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic of heart failure
SG11201702490PA (en) * 2014-10-10 2017-04-27 Akira Matsumori Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
US11193947B2 (en) 2016-06-03 2021-12-07 Cedars-Sinai Medical Center B-type natriuretic peptide proteolytic assay for cardiovascular disease risk assessment
WO2017210488A1 (en) * 2016-06-03 2017-12-07 Cedars-Sinai Medical Center B-type natriuretic peptide proteolytic assay for cardiovascular disease risk assessment
US20190257842A1 (en) * 2016-08-09 2019-08-22 Otsuka Pharmaceutical Co., Ltd. Method for assisting diagnosis of alzheimer's disease using urine biomarker
JP7414281B2 (ja) * 2017-08-08 2024-01-16 クイーンズランド ユニバーシティ オブ テクノロジー 初期心不全の診断方法
US11255844B2 (en) * 2018-03-06 2022-02-22 Fresenius Medical Care Holdings, Inc. Peritoneal dialysis systems and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
JP2676114B2 (ja) * 1990-04-16 1997-11-12 塩野義製薬株式会社 ｈＢＮＰを認識するモノクローナル抗体および該抗体を用いるｈＢＮＰの免疫測定法
DE50015291D1 (de) * 1999-01-29 2008-09-11 Roche Diagnostics Gmbh Verfahren zum Nachweis von N-terminalem proBNP
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
AUPS169202A0 (en) * 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
US8263325B2 (en) * 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US7109023B2 (en) * 2002-11-18 2006-09-19 Princeton Biomeditech Corporation Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
JP2006507510A (ja) * 2002-11-21 2006-03-02 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 組織低酸素症の体液マーカー
US7092759B2 (en) * 2003-07-30 2006-08-15 Medtronic, Inc. Method of optimizing cardiac resynchronization therapy using sensor signals of septal wall motion
US7887750B2 (en) * 2004-05-05 2011-02-15 Bayer Healthcare Llc Analytical systems, devices, and cartridges therefor
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions

Also Published As

Publication number Publication date
CA2605247A1 (en) 2006-11-16
EP1880221A1 (en) 2008-01-23
ATE482398T1 (de) 2010-10-15
JP2008541078A (ja) 2008-11-20
EP1722232A1 (en) 2006-11-15
JP4927825B2 (ja) 2012-05-09
CN103091497A (zh) 2013-05-08
ES2352351T3 (es) 2011-02-17
CN101171517B (zh) 2013-10-09
DE602006017058D1 (de) 2010-11-04
EP1880221B1 (en) 2010-09-22
WO2006120152A1 (en) 2006-11-16
US20110104813A1 (en) 2011-05-05
CN101171517A (zh) 2008-04-30

Similar Documents

Publication Publication Date Title
HK1119771A1 (en) Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
EP2315034A3 (en) Means and methods for assessing the risk of cardiac interventions based on GDF-15
ATE545032T1 (de) Diagnose von herz-kreislauf-erkrankung
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
WO2007062090A8 (en) Methods and compositions related to b cell assays
WO2005071407A3 (en) Methods of diagnosing acute coronary syndrome by measuring urotensin ii
WO2009059150A3 (en) Biomarkers for fatty liver disease and methods using the same
WO2010025393A3 (en) Protein biomarkers and methods for diagnosing kawasaki disease
WO2005118878A3 (en) Methods of screening for cell proliferation or neoplastic disorders
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2004089187A3 (en) Caries risk test for predicting and assessing the risk of disease
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
BRPI0410261A (pt) método de detecção de probnp natural
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
DK1756571T3 (da) Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
WO2004057341A3 (en) Cvd assay
WO2005048818A3 (en) Methods of diagnosing renal disease
WO2006002930A3 (en) FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
ATE473448T1 (de) Verfahren zur diagnose von herz-kreislauf- krankheiten
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2008080030A3 (en) Cardiovascular autoimmune disease panel and methods of using same
WO2005034737A3 (en) Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
WO2004107958A3 (en) Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
WO2006117688A3 (en) Diagnosis of heart failure
ATE437182T1 (de) Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum